单次追加瑞舒伐他汀对经皮冠状动脉介入治疗围手术期心肌标志物影响  

Effects of single adding dose of rovastatin on perioperative cardiac markers of percutaneous coronary intervention

作　　者：匡永东[1] 吕良冬[1] 王永光[1] 叶向阳[1] 郑巨克[1] 

机构地区：[1]浙江省瑞安市人民医院心血管内科,瑞安325200

出　　处：《海峡药学》2012年第7期79-81,共3页Strait Pharmaceutical Journal

摘　　要：目的观察经皮冠状动脉介入(PCI)治疗前追加20mg瑞舒伐他汀能否降低围手术期心肌标志物水平。方法 150例择期PCI冠心病,稳定型心绞痛患者随机分为两组:瑞舒伐他汀组予冠心病基础药物治疗,并在PCI前次日晚给予追加20mg瑞舒伐他汀;对照组仅予基础药物治疗。PCI后次日晨测肌钙蛋白I(TnI)、肌酸激酶同工酶(CK-MB)。结果术后瑞舒伐他汀组CK-MB和TnI水平显著低于对照组(P<0.01)。结论对于稳定型心绞痛患者,介入术前给予追加20mg瑞舒伐他汀能显著降低围术期心肌标志物水平。OBJECTIVE To investigate whether adding 20mg rovastatin prior to percutaneous coronary intervention（PCI） can efficiently reduce the incidence of perioperative cardiac markers. METHODS A total of 150 pa tients with stable angina pectoris who underwent selective PCI were enrolled in this study and randomized into two groups： the rovastation group and the control group. The rovastatin group was given a single loading of 20mg rovastatin 12 hours before receiving PCI on top of routine medical therapy. The control group was treated withroutine medication alone. TnI and CKMB were checked for all patients after PCI. RESULTS Postoperative CK MB and TnI levels in rovastatin group were significantly lower than those in control group. Moreover, the number of patients with CKMB and tnI level 3 times above the normal value in rovastatin group was significantly less than that in control group. CONCLUSION The level of cardiac markers and correspondi：ng incidence of myocardial infarction could be reduced by a single high loading dose of 20mg rovastatin given prior to PCI in stable angina patients with normal cardiac markers.

关 键 词：冠心病 经皮冠状动脉成形术 羟甲基戊二酰辅酶A还原酶抑制剂 

分 类 号：R969.4[医药卫生—药理学]